BRPI0707769A2 - tratamentos antivirais intravenosos - Google Patents

tratamentos antivirais intravenosos Download PDF

Info

Publication number
BRPI0707769A2
BRPI0707769A2 BRPI0707769-6A BRPI0707769A BRPI0707769A2 BR PI0707769 A2 BRPI0707769 A2 BR PI0707769A2 BR PI0707769 A BRPI0707769 A BR PI0707769A BR PI0707769 A2 BRPI0707769 A2 BR PI0707769A2
Authority
BR
Brazil
Prior art keywords
formula
compound
pharmaceutically acceptable
use according
acceptable salt
Prior art date
Application number
BRPI0707769-6A
Other languages
English (en)
Portuguese (pt)
Inventor
Yarlagadda Sudhakara Babu
Pooran Chand
Shanta Bantia
Shane Arnold
John Michael Kilpatrick
Original Assignee
Biocryst Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38169715&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0707769(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/US2006/013535 external-priority patent/WO2007117241A1/fr
Application filed by Biocryst Pharm Inc filed Critical Biocryst Pharm Inc
Publication of BRPI0707769A2 publication Critical patent/BRPI0707769A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
BRPI0707769-6A 2006-02-13 2007-02-12 tratamentos antivirais intravenosos BRPI0707769A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US77274806P 2006-02-13 2006-02-13
US60/772,748 2006-02-13
USPCT/US2006/013535 2006-04-12
PCT/US2006/013535 WO2007117241A1 (fr) 2006-04-12 2006-04-12 Traitements antiviraux intramusculaires
PCT/US2007/003755 WO2007095218A1 (fr) 2006-02-13 2007-02-12 Traitements antiviraux intraveineux

Publications (1)

Publication Number Publication Date
BRPI0707769A2 true BRPI0707769A2 (pt) 2011-05-10

Family

ID=38169715

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0707769-6A BRPI0707769A2 (pt) 2006-02-13 2007-02-12 tratamentos antivirais intravenosos

Country Status (11)

Country Link
EP (1) EP1986626A1 (fr)
JP (3) JP2009538822A (fr)
KR (9) KR102194015B1 (fr)
AU (2) AU2007215156A1 (fr)
BR (1) BRPI0707769A2 (fr)
CA (1) CA2642260C (fr)
EA (1) EA025483B1 (fr)
HK (1) HK1212250A1 (fr)
MX (2) MX2020002008A (fr)
MY (1) MY166063A (fr)
WO (1) WO2007095218A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102194015B1 (ko) * 2006-02-13 2020-12-22 바이오크리스트 파마수티컬즈, 인코퍼레이티드 정맥내 항바이러스 치료
CN101367750B (zh) * 2007-08-14 2012-05-23 中国人民解放军军事医学科学院毒物药物研究所 (1s,2s,3s,4r)-3-[(1s)-1-乙酰氨-2-乙基-丁基]-4-胍基-2-羟基-环戊基-1-羧酸水合物及其医药用途
KR20220033561A (ko) 2020-09-07 2022-03-17 주식회사 경보제약 페라미비르 화합물을 포함하는 프리믹스 제형의 제약학적 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE322163T1 (de) * 1996-06-14 2006-04-15 Biocryst Pharm Inc Substituierte cyclopentanderivate die als neuramidase-inhibitoren nuetzlich sind
AU2200199A (en) * 1997-12-17 1999-07-19 Biocryst Pharmaceuticals, Inc. Substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors
GB0015324D0 (en) * 2000-06-22 2000-08-16 Biota Scient Management Medicaments
KR102194015B1 (ko) * 2006-02-13 2020-12-22 바이오크리스트 파마수티컬즈, 인코퍼레이티드 정맥내 항바이러스 치료

Also Published As

Publication number Publication date
KR20180024027A (ko) 2018-03-07
HK1212250A1 (en) 2016-06-10
KR102194015B1 (ko) 2020-12-22
KR20210076189A (ko) 2021-06-23
KR101992585B9 (ko) 2022-09-20
MX2020002008A (es) 2020-07-13
JP6073202B2 (ja) 2017-02-01
MY166063A (en) 2018-05-23
JP2013256527A (ja) 2013-12-26
KR102267754B1 (ko) 2021-06-23
KR20160129105A (ko) 2016-11-08
EA025483B1 (ru) 2016-12-30
JP2015180695A (ja) 2015-10-15
KR101992585B1 (ko) 2019-06-25
CA2642260A1 (fr) 2007-08-23
AU2007215156A1 (en) 2007-08-23
KR102475176B1 (ko) 2022-12-07
KR20190072681A (ko) 2019-06-25
KR20080096829A (ko) 2008-11-03
JP2009538822A (ja) 2009-11-12
AU2013216632A1 (en) 2013-08-29
AU2013216632B2 (en) 2016-09-01
KR20200143519A (ko) 2020-12-23
KR20210135632A (ko) 2021-11-15
EP1986626A1 (fr) 2008-11-05
CA2642260C (fr) 2016-08-09
EA200870263A1 (ru) 2009-06-30
MX2008010394A (es) 2009-01-12
WO2007095218A1 (fr) 2007-08-23
KR20230003248A (ko) 2023-01-05
KR20140132778A (ko) 2014-11-18
KR102323339B1 (ko) 2021-11-08

Similar Documents

Publication Publication Date Title
BR112020006950A2 (pt) composições farmacêuticas injetáveis estabilizadas de l-epinefrina
US11464755B2 (en) Antiviral treatments
BRPI0707769A2 (pt) tratamentos antivirais intravenosos
CN102821605A (zh) 改进的稳定的（e）-4-羧基苯乙烯基-4-氯苄基砜水性制剂
JP2020536089A (ja) アセトアミノフェン−プレガバリン組み合わせ及び疼痛を処置する方法
JP2009538822A5 (fr)
BRPI0621552A2 (pt) tratamentos antivirais intramusculares
AU2016262644A1 (en) Intravenous antiviral treatments
PT2136816E (pt) Oleilfosfocolina
US12121503B2 (en) Antiviral treatments
CN106928308B (zh) 蓑衣莲酮的前药及其应用
KR20080113099A (ko) 근육내 항바이러스 치료

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]